189 related articles for article (PubMed ID: 9682344)
1. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine.
Kistner O; Barrett PN; Mundt W; Reiter M; Schober-Bendixen S; Dorner F
Vaccine; 1998; 16(9-10):960-8. PubMed ID: 9682344
[TBL] [Abstract][Full Text] [Related]
2. Development of a Vero cell-derived influenza whole virus vaccine.
Kistner O; Barrett PN; Mundt W; Reiter M; Schober-Bendixen S; Eder G; Dorner F
Dev Biol Stand; 1999; 98():101-10; discussion 111. PubMed ID: 10494963
[TBL] [Abstract][Full Text] [Related]
3. [Development of a novel influenza vaccine derived from a continuous cell line].
Kistner O; Barrett N; Mundt W; Reiter M; Schober-Bendixen S; Eder G; Dorner F
ALTEX; 2001; 18(1):50-4. PubMed ID: 11248852
[TBL] [Abstract][Full Text] [Related]
4. A novel mammalian cell (Vero) derived influenza virus vaccine: development, characterization and industrial scale production.
Kistner O; Barrett PN; Mundt W; Reiter M; Schober-Bendixen S; Eder G; Dorner F
Wien Klin Wochenschr; 1999 Mar; 111(5):207-14. PubMed ID: 10226351
[TBL] [Abstract][Full Text] [Related]
5. [Cultural influenza vaccines].
Gendon IuZ
Vopr Virusol; 2002; 47(6):4-11. PubMed ID: 12508674
[TBL] [Abstract][Full Text] [Related]
6. Comparison of immunogenicity of cell-and egg-passaged viruses for manufacturing MDCK cell culture-based influenza vaccines.
Shin D; Park KJ; Lee H; Cho EY; Kim MS; Hwang MH; Kim SI; Ahn DH
Virus Res; 2015 Jun; 204():40-6. PubMed ID: 25892718
[TBL] [Abstract][Full Text] [Related]
7. Immortalized chick embryo cell line adapted to serum-free growth conditions and capable of replicating human and reassortant H5N1 influenza strains for vaccine production.
Coussens PM; Smith KA; Weber PS; Colvin CJ
Vaccine; 2011 Nov; 29(47):8661-8. PubMed ID: 21911025
[TBL] [Abstract][Full Text] [Related]
8. Influenza viruses production: Evaluation of a novel avian cell line DuckCelt®-T17.
Petiot E; Proust A; Traversier A; Durous L; Dappozze F; Gras M; Guillard C; Balloul JM; Rosa-Calatrava M
Vaccine; 2018 May; 36(22):3101-3111. PubMed ID: 28571695
[TBL] [Abstract][Full Text] [Related]
9. Growth and immunogenicity of influenza viruses cultivated in Vero or MDCK cells and in embryonated chicken eggs.
Govorkova EA; Kodihalli S; Alymova IV; Fanget B; Webster RG
Dev Biol Stand; 1999; 98():39-51; discussion 73-4. PubMed ID: 10494958
[TBL] [Abstract][Full Text] [Related]
10. Serum-free microcarrier based production of replication deficient influenza vaccine candidate virus lacking NS1 using Vero cells.
Chen A; Poh SL; Dietzsch C; Roethl E; Yan ML; Ng SK
BMC Biotechnol; 2011 Aug; 11():81. PubMed ID: 21835017
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of immune responses to inactivated influenza vaccines prepared in embryonated chicken eggs and MDCK cells in a mouse model.
Nerome K; Kumihashi H; Nerome R; Hiromoto Y; Yokota Y; Ueda R; Omoe K; Chiba M
Dev Biol Stand; 1999; 98():53-63; discussion 73-4. PubMed ID: 10494959
[TBL] [Abstract][Full Text] [Related]
12. Egg- or cell culture-derived hemagglutinin mutations impair virus stability and antigen content of inactivated influenza vaccines.
Nakowitsch S; Waltenberger AM; Wressnigg N; Ferstl N; Triendl A; Kiefmann B; Montomoli E; Lapini G; Sergeeva M; Muster T; Romanova JR
Biotechnol J; 2014 Mar; 9(3):405-14. PubMed ID: 24323790
[TBL] [Abstract][Full Text] [Related]
13. The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines.
Pau MG; Ophorst C; Koldijk MH; Schouten G; Mehtali M; Uytdehaag F
Vaccine; 2001 Mar; 19(17-19):2716-21. PubMed ID: 11257414
[TBL] [Abstract][Full Text] [Related]
14. Development and preclinical testing of HNVAC, a cell culture-based H1N1 pandemic influenza vaccine from India.
Hegde NR; Kumar D; Rao PP; Kumari PK; Kaushik Y; Ravikrishnan R; Prasad SD; Ella KM
Vaccine; 2014 Jun; 32(29):3636-43. PubMed ID: 24801052
[TBL] [Abstract][Full Text] [Related]
15. Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains.
Tree JA; Richardson C; Fooks AR; Clegg JC; Looby D
Vaccine; 2001 May; 19(25-26):3444-50. PubMed ID: 11348709
[TBL] [Abstract][Full Text] [Related]
16. Use of MDCK cells for production of live attenuated influenza vaccine.
Liu J; Shi X; Schwartz R; Kemble G
Vaccine; 2009 Oct; 27(46):6460-3. PubMed ID: 19559113
[TBL] [Abstract][Full Text] [Related]
17. Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine.
Johansson BE
Vaccine; 1999 Apr; 17(15-16):2073-80. PubMed ID: 10217609
[TBL] [Abstract][Full Text] [Related]
18. High-yield production of a stable Vero cell-based vaccine candidate against the highly pathogenic avian influenza virus H5N1.
Zhou F; Zhou J; Ma L; Song S; Zhang X; Li W; Jiang S; Wang Y; Liao G
Biochem Biophys Res Commun; 2012 May; 421(4):850-4. PubMed ID: 22554519
[TBL] [Abstract][Full Text] [Related]
19. A Vero-cell-adapted vaccine donor strain of influenza A virus generated by serial passages.
Hu W; Zhang H; Han Q; Li L; Chen Y; Xia N; Chen Z; Shu Y; Xu K; Sun B
Vaccine; 2015 Jan; 33(2):374-81. PubMed ID: 25448099
[TBL] [Abstract][Full Text] [Related]
20. Genetic engineering of live attenuated influenza viruses.
Jin H; Chen Z; Liu J; Kemble G
Methods Mol Biol; 2012; 865():163-74. PubMed ID: 22528159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
